News & Events

The Trial Ready Cohort-Down Syndrome (TRC-DS) begins

The Trial Ready Cohort-Down Syndrome (TRC-DS) begins

A pioneering international study that accelerates the inclusion of adults with Down Syndrome in clinical trials is starting at the Alzheimer-Down Unit of the Hospital de Sant Pau and the Fundació Catalana de Síndome de Down in Barcelona. The Trial Ready Cohort-Down...

Assessing the value of MRI for the diagnosis of tauopathies

Assessing the value of MRI for the diagnosis of tauopathies

MRI and tauopathies Progressive supranuclear palsy (PSP) and Corticobasal Degeneration (CBD) are two subtypes of Frontotemporal Lobular Degeneration characterized by cerebral accumulation of tau protein (tauopathies). These diseases present classically with motor...

Links:

Educational sessions:

Multimarker synaptic panels for FTD

Multimarker synaptic panels for FTD

Multimarker panels in FTD Frontotemporal dementia is the most common cause of early-onset dementia and the principal cause of FrontoTemporal Lobular Degeneration (FTLD). Approximately, 90–95% of FTLD cases are characterized by the accumulation in the brain of two...

Stability of Alzheimer biomarkers in CSF

Stability of Alzheimer biomarkers in CSF

Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal...

World Down Syndrome Day

World Down Syndrome Day

Today, March 21, the Memory Unit and the Alzheimer Down Unit celebrate World Down Syndrome Day. Because diversity enriches, we work to achieve an inclusive and equal world for...

Concordance between amyloid markers in CSF

Concordance between amyloid markers in CSF

Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is...

Victor Montal defends his Doctoral Thesis

Victor Montal defends his Doctoral Thesis

Víctor Montal Blancafort has presented today his Doctoral Thesis entitled “Complex neuroimaging changes in metabolite, cortical structures and regional vulnerabilities in the Alzheimer disease continuum“. The thesis, directed by Dr. Juan Fortea and...

Jordi Pegueroles defends his Doctoral Thesis

Jordi Pegueroles defends his Doctoral Thesis

In January 18th 2022, Jordi Pegueroles Monllau presented  his doctoral thesis entitled “The role of biomarkers in the current classification systems for Alzheimer’s Disease“. The thesis has been supervised by Dr. Juan Fortea and tutored by Dr....